[New oral anticoagulants in coronary artery disease]

Presse Med. 2017 Jul-Aug;46(7-8 Pt 1):714-718. doi: 10.1016/j.lpm.2017.06.004. Epub 2017 Jul 21.
[Article in French]

Abstract

Antiplatelet therapy is essential for the prevention of recurrent cardiovascular events in stable and unstable coronary artery disease. Oral anticoagulants have been rarely used for treatment of coronary artery disease. The new direct oral anticoagulants offer various molecules and dosages and may be used in coronary artery disease. Dedicated studies are currently being conducted to confirm the optimal doses and the ideal association of antithrombotic drugs in different settings of coronary artery disease.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy
  • Administration, Oral
  • Angioplasty, Balloon, Coronary
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / therapy
  • Coronary Artery Disease / drug therapy*
  • Dabigatran / pharmacology
  • Dabigatran / therapeutic use
  • Humans
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Pyridones / pharmacology
  • Pyridones / therapeutic use
  • Rivaroxaban / therapeutic use
  • Stents
  • Stroke

Substances

  • Anticoagulants
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban
  • Dabigatran